MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Interest Expense 2011-2026 | VIVO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.19 M | 1.88 M | 2.63 M | 1.94 M | 1.52 M | 1.64 M | 897 K | -1.02 M | -309 K | 4 K | 378 K | 352 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.63 M | -1.02 M | 926 K |
Quarterly Interest Expense Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 148 K | - | - | 341 K | 372 K | - | 444 K | 472 K | 534 K | 2 M | 703 K | 534 K | 767 K | 1.16 M | 448 K | 767 K | 363 K | 1.15 M | 375 K | 363 K | 395 K | 1.24 M | 407 K | 395 K | 423 K | 470 K | 427 K | 423 K | 96 K | -892 K | -99 K | 96 K | -582 K | -505 K | -257 K | -582 K | -220 K | 225 K | -160 K | -220 K | 128 K | 304 K | 31 K | 128 K | 316 K | 357 K | 36 K | 316 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2 M | -892 K | 303 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
81 M | $ 118.25 | -1.27 % | $ 35.9 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 22.5 | 9.44 % | $ 242 M |  China |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 22.42 | 27.6 % | $ 1.19 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.46 | 2.82 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.56 | -0.24 % | $ 682 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 176.94 | -2.0 % | $ 8.77 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 515.65 | -0.56 % | $ 14.9 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 193.78 | -2.18 % | $ 138 B | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.16 | -5.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.24 | -1.91 % | $ 2 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 132.72 | 0.35 % | $ 21.1 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.13 | -0.25 % | $ 488 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.63 | -1.58 % | $ 20 B |  Niderland |
 |
Guardant Health
GH
|
-10.5 M | $ 85.7 | 0.99 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.83 | -3.41 % | $ 91.8 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.2 | 4.27 % | $ 5.05 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.77 | -1.88 % | $ 282 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 115.58 | -0.79 % | $ 9.53 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 266.36 | -0.14 % | $ 22.2 B | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.57 | - | $ 2.67 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Celcuity
CELC
|
2.11 M | $ 125.25 | 1.44 % | $ 5.86 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.4 | 0.72 % | $ 92.3 M | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 5.0 | -3.66 % | $ 463 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 83.92 | -0.02 % | $ 5.66 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 516.0 | -2.95 % | $ 195 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.7 | -0.54 % | $ 61.9 M | Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 191.46 | 0.02 % | $ 21.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 5.17 | 0.58 % | $ 4.07 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 56.23 | -2.41 % | $ 3.36 B | USA |